SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Granules India’s arm gets USFDA’s nod for Colchicine Tablets

06 Feb 2020 Evaluate

Granules India’s wholly owned foreign subsidiary -- Granules Pharmaceuticals, Inc., has received approval from US Food & Drug Administration (USFDA) for the Abbreviated New Drug Application (ANDA) for Colchicine Tablets USP, 0.6 mg. It is bioequivalent to the reference listed drug product (RLD), Colcrys Tablets, 0.6 mg, of Takeda Pharmaceuticals USA, Inc. Colchicine Tablets are used for treatment of Familial Mediterranean Fever (FMF).

Granules India is manufacturer and supplier of pharmaceutical products. Its products include active pharmaceutical ingredients (API) like tablets, caplets, rapid release, pharmaceutical, formulation intermediates (PFI) and Finished Dosages (FDs).

Granules India Share Price

678.70 24.30 (3.71%)
20-Apr-2026 11:11 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1673.55
Dr. Reddys Lab 1238.10
Cipla 1239.20
Zydus Lifesciences 942.70
Lupin 2325.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×